The Latest Breaking News from AbbVie

5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold.

MarketBeat · May 26

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

Barchart · May 7

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat · May 2

What You Need to Know Ahead of AbbVie’s Earnings Release

AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Apr 2

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

MarketBeat · Mar 6

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

MarketBeat · Feb 5

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

Barchart · Jan 30

The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

Barchart · Jan 20

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

MarketBeat · Jan 16

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat · Jan 5